Lilly CDK4/6 inhibitors reached the clinical end of Phase 3.

Breast cancer is the most common cancer among women between the world's women.
estimates that 90% of breast cancers are diagnosed at an early stage.
most common subsypes are HR plus, HER2-subsype, accounting for 70% of the total number of breast cancer patients.
about 30 percent of patients diagnosed with HR-plus and HER2-early breast cancer still have a risk of cancer recurrence.
if they have certain clinical and/or pathological characteristics, such as cancer spreading to the lymph nodes, larger tumor volume and higher tumor grading levels, their risk of recurrence increases significantly.
patients need new treatment options to help prevent an early recurrence of breast cancer, potentially entering an incurable metastasis phase.
Verzenio (abemaciclib) is a CDK4/6 inhibitor that is activated by binding to the cell cycle protein D (D-cyclin).
In estrogen-positive breast cancer cell line, cell cycle proteins D1 and CDK4/6 promote phosphateization, cell cycle progression, and cell proliferation of retinal cytoblastoma protein (Rb).
Verzenio inhibits rb phosphorylation and blocks the progression of cell cycles from G1 to S, leading to cell aging and apoptosis.
has been approved by the FDA as a first-line therapy for patients with advanced breast cancer.
is a randomized, open-label, multi-center Phase 3 clinical trial that included 5,637 patients with high risk, lymph node-positive, HR-plus, and HER2-early breast cancer.
patients were randomly assigned to Verzenio plus standard assisted endocrine therapy group or simply standard assisted endocrine therapy group by 1:1.
results showed that the Verzenio combination therapy group statistically significantly reduced the risk of recurrence compared to the standard assisted endocrine treatment group.
plans to release the data at a medical conference later this year and will submit it to regulators around the world.
when they are diagnosed with high-risk early stage breast cancer, they do everything they can to prevent recurrence," he said.
As clinicians, we have the same goal," said Dr. Maura Dickler, vice president of oncology development at Lilly.
are very excited about the results of monarchE, and we may offer a new treatment option for patients at high risk of HR-HER2-early breast cancer.
" original title: Significantly reduce the risk of recurrence in patients with early breast cancer, Lilly CDK4/6 inhibitors reached the clinical end of phase 3.